Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition